The European Union has awarded EURE-CART (EURopean Endeavour for Chimeric Antigen Repector Therapies) with 5 Million Euro within the Horizon 2020 – Research and Innovation Framework Programme, section reserved to the new therapies for chronic diseases (including cancer).

To carry out this project and to reach clinical translation, a consortium of nine partners from five different EU countries has been established. acromion GmbH is one of these nine partners.

EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for conducting a first-in-man Phase I/II clinical trial